ClinicalTrials.gg
RecruitingNCT05791279Updated Oct 11, 2023

Electrocardiography-based Estimation of Heart Age to Improve Blood Pressure - a Pilot Study

An interventional study of Heart age in Cardiovascular Diseases and Hypertension, sponsored by Kronoberg County Council. Recruiting at 2 sites in Sweden. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-10-11.

Primary conditionHypertensionRegistry: Cardiovascular DiseasesReclassifiedWhy we changed it
Registry
Cardiovascular Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hypertension
Why
  1. The study's listed conditions name Hypertension, a narrower term within Cardiovascular Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Kronoberg County Council · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 2 months ago, but the record still lists the study as recruiting.
  • Started May 2023; still recruiting 3 years 6 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Study summary

Successfully communicating cardiovascular risk to patients is essential for achieving compliance to medication and lifestyle changes. An intuitive way to translate cardiovascular risk is to present a Heart Age; an ECG-based age-estimation from ECG changes which can be contrasted to a patient's chronological age. In this pilot study, the feasibility of a randomized controlled study (RCT) in which hypertensive patients in primary care will receive information about their ECG-based Heart Age in addition to standard care, or standard care alone, will be assessed, in preparation for a larger RCT.

Read the detailed description

Cardiovascular disease processes begin early and progress silently for many years. Fortunately, several risk-factors are modifiable, and cardiovascular risk can therefore be reduced for example by smoking cessation, dietary changes, increased physical activity in sedentary people and adherence to pharmacological risk factor reduction. To accomplish this, the patient must understand that he or she is at risk. One way to do this could be to present the risk as a "Heart Age", which can be contrasted to the patient's chronological age. In a previous study, an accurate Heart Age could be obtained using conventional, 10-second ECG recordings. The ECG analysis included conventional and basic ECG measurements such as heart rate and waveform amplitudes and durations, but also combinations of advanced ECG measures from 12-lead-ECG-derived vectorcardiography and waveform complexity.

However, it is not known whether the use of Heart Age can improve outcomes if applied in clinical care. To address this issue, a study in which patients, in addition to standard care, are randomized to either being presented with their Heart Age or not should be performed. In order to check the feasibility of such a randomized controlled study (RCT), a pilot study is necessary.

This study will evaluate the feasibility of randomizing patients with hypertension to either being presented with their Heart Age or not, in addition to standard care, by describing the recruitment dropout rate, the quality of the recorded ECG and the tolerability of the intervention (participant experience).

At the baseline visit a standardized resting blood pressure, height, weight and waist circumference will be measured. Baseline characteristics (age, sex, hypercholesterolemia, diabetes, ischemic heart disease, cerebrovascular disease, renal failure, heart failure, medications) will be recorded from the patient records. Unless a recent (\<1 month) ECG is available, a new resting ECG recording will be performed, and blood sampling will be done (total cholesterol, high-density lipoprotein [HDL], low-density lipoprotein [LDL] mmol/l, triglyceride mmol/mol, Hba1c (IFCC) mmol/mL, P-Creatinine (µmol/L). The participant will also receive a questionnaire for background information and information about tobacco and alcohol use, level of physical activity, dietary habits, medication adherence, quality of life and self-estimated health including estimating one's own risk of cardiovascular morbidity.

ECG-based Heart Age will be estimated for all participants but presented only to patients in the intervention arm. A follow-up visit will be performed 6 months after the baseline visit. At follow-up, the same measurements including the same questionnaires will be obtained. Participants in the intervention arm will also receive a questionnaire on their experience of receiving information about their Heart Age (tolerability).

02

Conditions studied

  • Cardiovascular Diseases
  • Hypertension

Browse trials for

03

In context

Hypertension Reclassified

6,114 studies on the registry are indexed under Hypertension; 912 are open to participants now.

This study's planned enrollment of 60 is below the median of 100 across 4,575 interventional studies indexed under Hypertension.

Browse Hypertension studies →

Lead sponsor

Kronoberg County Council is the lead sponsor of 13 studies on the registry; 6 are open to participants now.

Compared within Hypertension, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Cardiovascular Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Eligibility: Patients with hypertension and systolic blood pressure >140 mm Hg (measured during the inclusion period by doctor or nurse at the primary health care center)

Inclusion criteria

Inclusion Criteria:

  • Diagnosed hypertension (International classification of disease (ICD-10), I10.9)
  • 40 - 75 years

Exclusion criteria

Exclusion Criteria:

  • findings that are incompatible with or may significantly distort the Heart Age estimation (left/right bundle branch block, atrial fibrillation/flutter, tachycardia (≥100/min), abundant ventricular ectopic beats, misplaced ECG electrodes, missing leads, excessive signal noise/baseline)
  • Short (\<1 year)
  • Pregnancy, known secondary hypertension
  • Predicted inability to give due to either language difficulties, cognitive impairment or other.
  • Systolic blood pressure \<120 mmHg at the baseline visit
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Interventional arm

    The participants in the intervention group will receive information about their ECG-based Heart-Age and the Heart Age. The estimated Heart Age and Heart Age Gap will be presented in writing to the participants in the experimental arm within 2 weeks after the baseline visit. The presentation will include a brief and easy-to-understand description on how the Heart Age has been estimated. In addition, patients will receive information about general advice on how to improve blood pressure levels and reduce the risk of future cardiovascular disease by adopting a healthy lifestyle and adhering to the prescribed medication. This information will be the same for participants in the two study arms, and is based on recommendations from the European Society of Cardiology. For patients in the intervention group the ordinary primary care physicians will also be informed about the ECG-based Heart-Age.

    Other: Heart age

  • No intervention
    Control arm

    The control group will receive standard care according to routine care at the individual primary health care center, and receive the same general advice, on how to improve blood pressure levels and/or to reduce risks of future cardiovascular disease, as the participants in the intervention group.

Interventions

  • OtherHeart age

    information about their ECG-based Heart-Age and the Heart Age gap, i.e. the difference between chronological and ECG-based Heart Age.

06

What researchers measure

Primary outcomes

  1. Recruitment rate

    Number of patients being recruited within the specified time frame

    Time frame: 6 months

  2. Dropout rate

    Number of patients who do not complete follow-up

    Time frame: 6 months

  3. Quality

    Number of Heart Age estimations with adequate ECG signal quality

    Time frame: 6 months

  4. Tolerability of the intervention

    Tolerability of the intervention assessed through questionnaires.

    Time frame: 6 months

Secondary outcomes

  1. Blood pressure (systolic and diastolic)

    Change in blood pressure

    Time frame: 6 months

  2. HbA1c

    Change in HbA1c

    Time frame: 6 months

  3. Physical activity

    Change in physical activity assessed through questionnaires.

    Time frame: 6 months

  4. Dietary habits

    Change in dietary habits assessed through questionnaires.

    Time frame: 6 months

  5. Tobacco

    Change in tobacco use assessed through questionnaires.

    Time frame: 6 months

  6. Alcohol

    Change in alcohol use assessed through questionnaires.

    Time frame: 6 months

  7. Medication adherence

    Change in medication adherence assessed through questionnaires.

    Time frame: 6 months

  8. Risk perception

    Change in risk perception assessed through questionnaires.

    Time frame: 6 months

  9. Body-mass index (BMI)

    Change in BMI

    Time frame: 6 months

  10. Heart Age

    Change in Heart Age

    Time frame: 6 months

07

Study locations

2 of 2 sites recruiting
  • Ryd Vardcentral
    Ryd, Sweden
    Recruiting
    • Karin Svensson Soderberg, MD · Contact
  • Tingsryd Vardcentral
    Tingsryd, Sweden
    Recruiting
    • Karin Svensson Soderberg, MD · Contact
08

References and documents

Publications

  • Lindow T, Palencia-Lamela I, Schlegel TT, Ugander M. Heart age estimated using explainable advanced electrocardiography. Sci Rep. 2022 Jun 14;12(1):9840. doi: 10.1038/s41598-022-13912-9. PubMed 35701514 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Sep 2024, 16 months after the start.

Of 1,403 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 16 months is below that.

Counting every sponsor, half of 1,498 studies reached it within 23 months; a quarter within 10 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2023
First posted
Mar 30, 2023
StartActual
May 1, 2023
Primary completionEst.
Sep 1, 2024
CompletionEst.
Sep 1, 2024
Last update
Oct 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05791279
Lead sponsor
Kronoberg County Council
Collaborators
Lund University, University of Sydney
Responsible party
Sponsor
First posted
Mar 30, 2023
Start date
May 1, 2023
Primary completion
Sep 1, 2024 (estimated)
Completion
Sep 1, 2024 (estimated)
Last update
Oct 11, 2023

Study contacts

Thomas Lindow, MD, PhD
Contact
thomas.akesson_lindow@med.lu.se
+46470588000
Karin Svensson Söderberg, MD
Contact
karin.svensson-soderberg@kronoberg.se
Thomas Lindow, MD, PhD
principal investigator · Region Kronoberg, Sweden; Lund University, Lund, Sweden

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion